Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime siv-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 629-637

  Patterson, L Jean ^a   Kuate, Seraphin ^a,d   Daltabuit Test, Mara ^a   Li, Qingsheng ^b,e   Xiao, Peng ^a   McKinnon, Katherine ^a   DiPasquale, Janet ^a   Cristillo, Anthony ^c   Venzon, David ^a   Haase, Ashley ^b   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Advanced BioScience Laboratories   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF NEBRASKA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN A; SIMIAN IMMUNODEFICIENCY VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BIOACCUMULATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LUNG FLUID; LUNG LAVAGE; MACROPHAGE; MALE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; RECTAL MACROPHAGE; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; TISSUE SECTION; VIRUS ENTRY; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, VIRAL; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN A, SECRETORY; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MACROPHAGES; MALE; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC;

EID: 84860343750     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00010-12     Document Type: Article

References (42)

1. Bogers WM, et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382:217-255.
2. Brocca-Cofano E, et al. 2011. Vaccine-elicited SIV and HIV envelopespecific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 29:3310-3319.
3. Buchbinder SP, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
4. Buge SL, et al. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531-8541. (Pubitemid 27446435)
5. Chen K, Cerutti A. 2010. Vaccination strategies to promote mucosal antibody responses. Immunity 33:479-491.
6. Cuburu N, et al. 2009. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 183:7851-7859.
7. Cuburu N, et al. 2007. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25:8598-8610. (Pubitemid 350192038)
8. Curran RM, et al. 2009. Vaginal delivery of the recombinant HIV-1 clade C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 27:6791-6798.
9. Duerr A. 2010. Update on mucosal HIV vaccine vectors. Curr. Opin. HIV AIDS 5:397-403.
10. + T cells and generation of specific antibodies following mucosal immunization. J. Immunol. 183:5032-5041.
11. Florese RH, et al. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared to multigenic vaccines. J. Immunol. 182:3718-3727.
12. Gaydos CA, Gaydos JC. 1995. Adenovirus vaccines in the U.S. military. Mil. Med. 160:300-304.
13. Gomez-Roman VR, et al. 2006. An adenovirus-based HIV subtype-B prime/boost vaccine regimen elicits antibodies mediating broad antibodydependent cellular cytotoxicity against non-subtype-B strains. J. Acquir. Immune Defic. Syndr. 43:270-277. (Pubitemid 44674006)
14. Gomez-Roman VR, et al. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:2185-2189. (Pubitemid 40223963)
15. Graham BS, et al. 2010. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol. 3:475-486.
16. Hervouet C, et al. 2010. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28:5582-5590.
17. Hidajat R, et al. 2010. Construction and immunogenicity of replicationcompetent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV-1 strains. Vaccine 28:3963-3971.
18. Hidajat R, et al. 2009. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83:791-801.
19. Kalyanaraman VS, et al. 1990. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 6:371-380. (Pubitemid 20278797)
20. + T lymphocytes. J. Virol. 84:5986-5996.
21. Lakhashe SK, et al. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29:5611-5622.
22. Lemiale et al. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078-10087. (Pubitemid 37122089)
23. + T cells. Nature 434:1148-1152. (Pubitemid 40663495)
24. + T cell responses following replicationdefective adenovirus serotype 5 immunization are dependent on CD11c dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J. Immunol. 185:1513-1521.
25. Lore K, et al. 2007. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 179:1721-1729.
26. Lubeck MD, et al. 1994. Immunogenicity of recombinant adenovirushuman immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res. Hum. Retroviruses 10:1443-1449. (Pubitemid 24382196)
27. Lubeck MD, et al. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651-658. (Pubitemid 27264975)
28. + T cell responses. Virology 353:83-98. (Pubitemid 44389685)
29. Mannering SI, et al. 2003. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J. Immunol. Methods 283: 173-183. (Pubitemid 37501068)
30. Negri DRM, et al. 2010. Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 28:4175-4180.
31. Patterson LJ, et al. 2011. Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 411:87-102.
32. Patterson LJ, et al. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hrsimian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77:8607-8620. (Pubitemid 36936072)
33. Patterson LJ, Robert-Guroff M. 2008. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin. Biol. Ther. 8:1347-1363.
34. Peng B, et al. 2005. Replicating rather than nonreplicating adenovirushuman immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high titer antibodies. J. Virol. 79:10200-10209. (Pubitemid 41098561)
35. Qureshi H, et al. 2012. Low dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb Step trial of a similar HIV-1 vaccine. J. Virol. 86:2239-2250.
36. Wang S-W, et al. 2004. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res. Hum. Retroviruses 20:846-859. (Pubitemid 39121205)
37. Wira CR, Fahey JV. 2008. A new strategy to understand how HIV infects women: Identification of a window of vulnerability during the menstrual cycle. AIDS 22:1909-1917.
38. 89.6P challenge in rhesus macaques. J. Virol. 84:7161-7173.
39. mac251 challenge. J. Virol. 86:4644-4657.
40. Zhang Y, Huang W, Ornelles DA, Gooding LR. 2010. Modeling adenovirus latency in human lymphocyte cell lines. J. Virol. 84:8799-8810.
41. mac251 challenge by a replication-competent Ad5hr-SIV env/rev and Ad5hr-SIV gag recombinant priming/gp120 boosting regimen. J. Virol. 77:8354-8365. (Pubitemid 36871464)
42. Zolla-Zazner S, et al. 1998. Induction of neutralizing antibodies to T cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime/boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.